Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011–2021)

Capecitabine plus temozolomide (CAPTEM) improves progression-free survival (PFS) in pancreatic endocrine and neuroendocrine neoplasms (PNENs), yet its real-world effectiveness across other endocrine and neuroendocrine neoplasm (ENEN) subtypes remains uncertain. We conducted a retrospective populatio...

Description complète

Détails bibliographiques

Auteurs principaux:	Alda Aleksi, Kaiden D. Jobin, Malek B. Hannouf, Patrik Husi, Heather Halperin, Chris White-Gloria, Tasnima Abedin, Dean Ruether
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2026-05-01
Collection:	Current Oncology
Sujets:	neuroendocrine neoplasms endocrine neoplasms CAPTEM real-world retrospective cohort overall survival
Accès en ligne:	https://www.mdpi.com/1718-7729/33/5/289
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!